Drug intelligence / Profile preview

astatine-211-labelled trastuzumab

Lead developer
University of Gothenburg
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
Administration
Intperitoneal, Intravenous
01

Overview

astatine-211-labelled trastuzumab (also known as 211At-trastuzumab) is a clinical-stage targeted alpha therapy (TAT) radiopharmaceutical. It consists of the humanized anti-HER2 monoclonal antibody trastuzumab radiolabeled with the alpha-emitting radionuclide astatine-211 ($^{211}\text{At}$). The drug is designed to selectively target and destroy human epidermal growth factor receptor 2 (HER2)-expressing cancer cells. Upon binding to HER2, the high linear energy transfer (LET) alpha particles emitted by the decay of astatine-211 induce localized, irreparable double-strand DNA breaks in the tumor cells, minimizing damage to surrounding healthy tissues. It is primarily being developed for the intraperitoneal treatment of disseminated HER2-positive cancers, such as ovarian cancer, and has also been investigated preclinically for gastric cancer and uterine serous carcinoma.

Other names
211At-labeled trastuzumab211At-labelled trastuzumab211At-tras211At-trastuzumabastatinated trastuzumabastatine-211-labeled trastuzumabastatine211-labeled trastuzumabastatine 211-labeled trastuzumab
02

Identity

Drug type
Antibody-Based Therapeutics
Originator
University of Gothenburg
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide ConjugatesAlpha Emitters
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
gastric cancer and precursor lesionsPreclinicalActive
ovarian cancer and premalignant lesionsIn developmentActive
serous endometrial carcinomaPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • University of GothenburgOriginator · Lead developer
07

Patents & exclusivity

Patents
2

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
273
Drugs in the lead indication
681

Lead indication: gastric cancer and precursor lesions

Most advanced in the lead indication

  1. aminocaproic acidApproved
  2. capecitabineApproved
  3. dacomitinibApproved
  4. doxorubicinApproved
  5. lazertinibApproved

Beyond the preview

Go deeper on astatine-211-labelled trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on astatine-211-labelled trastuzumab.

Work on astatine-211-labelled trastuzumab? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call